What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

5 November 2020

Two young PRIME scientists awarded with prestigious grant in The Netherlands

Dr. Janita Bralten from Radboudumc and Dr. Willemijn Jansen from Maastricht University have each obtained a prestigious research grant from the Dutch Research Council. This VENI-grant awards researchers who recently obtained their PhD with 250,000 euro’s to further develop their research ideas for a period of three years.

Dr. Janita Bralten aims to gain a better understanding of psychiatric disorders based on genetic traits. She will do this by investigating genetic subgroups in the total population that are related to psychiatric problems, going beyond psychiatric diagnoses. Dr. Willemijn Jansen will investigate why some people are resilient to developing Alzheimer’s symptoms, even though their brains do show markers of pathology. For this she will study proteins in cerebrospinal fluid (the fluid that’s present in the brain and spinal cord). Through this research she hopes to find clues that help to develop new treatments for Alzheimer’s Disease.

You can read more about the VENI-grants here: https://www.nwo.nl/en/news/161-researchers-awarded-nwo-veni-grant-worth-250000-euros

More News

Social media

more social media
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847879.
This website reflects only the view of the authors and the European Commission is not responsible for any use that may be made of the information it contains‍.
‍
© 2020 PRIME